Know the Latest About COVID-19 Monoclonal Antibodies
Recent evidence and rising cases will renew focus on COVID-19 monoclonal antibodies...casirivimab/imdevimab (Regen-COV), etc.
Patients. Early data now suggest casirivimab/imdevimab reduces mortality in patients HOSPITALIZED due to COVID-19.
But it's not authorized for these patients yet...and the dose showing benefit is over 6 times the current authorized dose.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote